|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Proneuron Biotechnologies, Inc. (US Branch) And Cell Design Of Atlanta To Establish A New Cell Processing Facility In Atlanta To Support The Current Phase II Trial Of ProCord For Complete Spinal Cord Injury
10/19/2005 5:11:37 PM
Proneuron Biotechnologies, Inc and Cell Design, L.L.C. announced today that the two companies have entered into an agreement to establish a new human cell processing facility in Atlanta to support the current Phase II study of Proneuron's Procord, autologous incubated macrophages for complete spinal cord injury. Cell Design, a subsidiary of Cell Dynamics, LLC, will provide the required cell processing facility for the manufacturing of ProCord in the southeast region of the U.S. for this international, multi-center, randomized-controlled clinical trial. The agreement with Cell Design will support Proneuron's collaboration with the Shepherd Center in Atlanta, which is anticipated to begin enrollment in 2004 and is already taking an active role in the study. Upon receipt of the requisite approval of the United States Food and Drug Administration, the facility will also provide for the commercial manufacturing of ProCord.
|
|
|
|
|
|
|
|
|
|
|